- Cancer-focused biotech Rigel Pharmaceuticals ( NASDAQ: RIGL ) announced Thursday the U.S. availability of its oral therapy Rezlidhia for adults with relapsed or refractory (R/R) acute myeloid leukemia (AML). The launch comes days after the FDA approval of Rezlidhia early this month.
- Accordingly, the drug known as olutasidenib in generic terms will be available as a prescription medicine for AML patients with a susceptible isocitrate dehydrogenase-1 (IDH1) genetic mutation as detected by an FDA-approved test.
- The company has set the wholesale acquisition cost or list price for Rezlidhia at $32,200 per month.
- "REZLIDHIA is Rigel's second commercial product and is a new and promising oral treatment option for mIDH1 R/R AML patients who typically experience poor clinical outcomes," Chief Executive Raul Rodriguez noted.
- Rigel ( RIGL ) has teamed up with Forma Therapeutics, a unit of Novo Nordisk ( NVO ) ( OTCPK:NONOF ), to develop and commercialize Rezlidhia outside the U.S.
For further details see:
Rigel launches leukemia therapy in U.S.